Alex Biese

The FDA has granted orphan drug designation to the investigational therapy BA-101 for the treatment of patients with glioblastoma.

Here is an overview of cancers including bladder cancer, kidney cancer and testicular cancer.

The FDA granted Breakthrough Therapy designation to olomorasib plus Keytruda for unresectable advanced or metastatic NSCLC with a KRAS G12C mutation.

TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder cancer.

In observation of Leukemia Awareness Month in September, CURE spoke with an expert about basics of the disease.

CURE spoke with Dr. Ryan Kahn of Miami Cancer Institute for Ovarian Cancer Awareness Month.

The FDA has approved the NDA for Camcevi ETM for the treatment of advanced prostate cancer.

In HPV15-positive first-line recurrent and/or metastatic head and neck cancer, PDS0101 and Keytruda elicited median overall survival more than three years.

Here is a primer on what patients who have received a diagnosis of gastrointestinal cancer need to know.

The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for patients with stage 2 colorectal cancer after surgery.

In patients with high-risk myelodysplastic syndromes, hypomethylating agents are underutilized, particularly among older, female and non-White patients.

The FDA’s accelerated approval of Modeyso for diffuse midline glioma with an H3 K27M mutation sets the stage for more treatment advancements.

This guide provides an overview of bladder cancer, from diagnosis to treatment, helping patients understand options, manage side effects, and plan care.

CURE spoke with an expert about the needs of children in families living with cancer during back-to-school season.

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung cancer.

CURE spoke with a clinical social worker about issues faced by families dealing with cancer as kids return to school.

A nationwide survey of patients and caregivers has found educational and financial disparities in brain cancer care.

The FDA has granted fast track designation to HLD-0915 for metastatic castration-resistant prostate cancer.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Among patients with advanced gastrointestinal stromal tumors, Gleevec and Mektovi was associated with benefits in progression and survival.

Long-term follow-up data from the phase 3 MANIFEST 2 clinical trial have been revealed.

Among patients with chronic lymphocytic leukemia, immunoglobulin replacement therapy is not associated with a reduced risk of serious infections.

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

An artificial intelligence-based image analysis model has more accurately predicted cancer biomarkers and outcomes compared with conventional methods.

The U.S. FDA granted accelerated approval to Modeyso for patients with diffuse midline glioma with an H3 K27M mutation with progressive disease.

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin.

CURE spoke with experts about radical cystectomy, or surgical removal of the bladder, for patients with bladder cancer.

CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.